319 related articles for article (PubMed ID: 28867112)
1. PET-Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors.
Pinho DF; Subramaniam RM
PET Clin; 2017 Oct; 12(4):407-421. PubMed ID: 28867112
[No Abstract] [Full Text] [Related]
2. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of
Sato A; Masui T; Yogo A; Uchida Y; Nakano K; Anazawa T; Nagai K; Takaori K; Nakamoto Y; Uemoto S
J Hepatobiliary Pancreat Sci; 2020 Jul; 27(7):414-420. PubMed ID: 32196985
[TBL] [Abstract][Full Text] [Related]
4. The Role of PET/CT in the Imaging of Pancreatic Neoplasms.
Duan H; Baratto L; Iagaru A
Semin Ultrasound CT MR; 2019 Dec; 40(6):500-508. PubMed ID: 31806148
[TBL] [Abstract][Full Text] [Related]
5. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
Crown A; Rocha FG; Raghu P; Lin B; Funk G; Alseidi A; Hubka M; Rosales J; Lee M; Kennecke H
J Surg Oncol; 2020 Mar; 121(3):480-485. PubMed ID: 31853990
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
[TBL] [Abstract][Full Text] [Related]
7. Incidental finding of a breast carcinoma on Ga-68-DOTA-1-Nal3-octreotide positron emission tomography/computed tomography performed for the evaluation of a pancreatic neuroendocrine tumor: A case report.
Sampaio Vieira T; Borges Faria D; Souto Moura C; Francisco E; Barroso S; Pereira de Oliveira J
Medicine (Baltimore); 2018 Sep; 97(36):e11878. PubMed ID: 30200073
[TBL] [Abstract][Full Text] [Related]
8. Current status and future prospects of PET-imaging applications in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).
Papadakis GZ; Karantanas AH; Marias K; Millo C
Eur J Radiol; 2021 Oct; 143():109932. PubMed ID: 34482177
[TBL] [Abstract][Full Text] [Related]
9. Combined 18F-FDG PET/CT and 68Ga DOTATATE PET/CT "Superscan" in Metastatic Pancreatic Neuroendocrine Tumor.
Chan M; Schembri GP
Clin Nucl Med; 2017 Feb; 42(2):108-109. PubMed ID: 27997429
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
11. State of the Art and Recent Developments of Radiopharmaceuticals for Pancreatic Neuroendocrine Tumors Imaging.
Carollo A; Papi S; Grana CM; Mansi L; Chinol M
Curr Radiopharm; 2019; 12(2):107-125. PubMed ID: 30843499
[TBL] [Abstract][Full Text] [Related]
12. [Pancreatic neuroendocrine neoplasms].
Beiderwellen K; Sabet A; Lauenstein TC; Lahner H; Poeppel TD
Radiologe; 2016 Apr; 56(4):348-54. PubMed ID: 27003413
[TBL] [Abstract][Full Text] [Related]
13. Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions.
Cingarlini S; Ortolani S; Salgarello M; Butturini G; Malpaga A; Malfatti V; DʼOnofrio M; Davì MV; Vallerio P; Ruzzenente A; Capelli P; Citton E; Grego E; Trentin C; De Robertis R; Scarpa A; Bassi C; Tortora G
Pancreas; 2017 Jan; 46(1):42-47. PubMed ID: 27906872
[TBL] [Abstract][Full Text] [Related]
14. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.
Prasad V; Tiling N; Denecke T; Brenner W; Plöckinger U
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206
[TBL] [Abstract][Full Text] [Related]
15. A patient with nonfunctional pancreatic neuroendocrine tumor and incidental metachronous colon carcinoma detected by positron emission tomography: case report.
Demirkan B; Unek IT; Eriksson B; Akarsu M; Durak H; Sağol O; Obuz F; Binicier C; Füzün M; Alakavuklar M
Turk J Gastroenterol; 2009 Sep; 20(3):214-9. PubMed ID: 19821205
[TBL] [Abstract][Full Text] [Related]
16. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.
Yao J; Gan G; Farlow D; Laurence JM; Hollands M; Richardson A; Pleass HC; Lam VW
ANZ J Surg; 2012 Mar; 82(3):140-4. PubMed ID: 22510123
[TBL] [Abstract][Full Text] [Related]
17. Carbidopa-assisted
Helali M; Addeo P; Heimburger C; Detour J; Goichot B; Bachellier P; Namer IJ; Taïeb D; Imperiale A
Ann Nucl Med; 2016 Nov; 30(9):659-668. PubMed ID: 27485404
[TBL] [Abstract][Full Text] [Related]
18. Gamma Emitters in Pancreatic Endocrine Tumors Imaging in the PET Era: Is there a Clinical Space for 99mTc-peptides?
Briganti V; Cuccurullo V; Di Stasio GD; Mansi L
Curr Radiopharm; 2019; 12(2):156-170. PubMed ID: 30827276
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
Deppen SA; Liu E; Blume JD; Clanton J; Shi C; Jones-Jackson LB; Lakhani V; Baum RP; Berlin J; Smith GT; Graham M; Sandler MP; Delbeke D; Walker RC
J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865
[TBL] [Abstract][Full Text] [Related]
20.
Satoh K; Sadowski SM; Dieckmann W; Quezado M; Nilubol N; Kebebew E; Patel D
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):714-721. PubMed ID: 27638678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
